Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon

Background: Sub-Saharan Africa (SSA) has a high proportion of premenopausal hormone receptor negative breast cancer. Previous studies reported a strikingly high prevalence of germline mutations in BRCA1 and BRCA2 among Nigerian patients with breast cancer. It is unknown if this exists in other SSA countries. Methods: Breast cancer cases, unselected for age at diagnosis and family history, were recruited from tertiary hospitals in Kampala, Uganda and Yaoundé, Cameroon. Controls were women without breast cancer recruited from the same hospitals and age-matched to cases. A multigene sequencing panel was used to test for germline mutations. Results: There were 196 cases and 185 controls with a mean age of 46.2 and 46.6 years for cases and controls, respectively. Among cases, 15.8% carried a pathogenic or likely pathogenic mutation in a breast cancer susceptibility gene: 5.6% in BRCA1, 5.6% in BRCA2, 1.5% in ATM, 1% in PALB2, 0.5% in BARD1, 0.5% in CDH1, and 0.5% in TP53. Among controls, 1.6% carried a mutation in one of these genes. Cases were 11-fold more likely to carry a mutation compared with controls (OR = 11.34; 95% confidence interval, 3.44–59.06; P < 0.001). The mean age of cases with BRCA1 mutations was 38.3 years compared with 46.7 years among other cases without such mutations (P = 0.03). Conclusions: Our findings replicate the earlier report of a high proportion of mutations in BRCA1/2 among patients with symptomatic breast cancer in SSA. Impact: Given the high burden of inherited breast cancer in SSA countries, genetic risk assessment could be integrated into national cancer control plans.

[1]  Anjali D. Zimmer,et al.  Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines. , 2019, The Journal of molecular diagnostics : JMD.

[2]  T. Walsh,et al.  Inherited Breast Cancer in Nigerian Women , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[4]  C. Adebamowo,et al.  Development of a Breast Cancer Risk Prediction Model for Women in Nigeria , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[5]  Anjali D. Zimmer,et al.  A machine learning model to determine the accuracy of variant calls in capture-based next generation sequencing , 2018, BMC Genomics.

[6]  O. Olopade,et al.  Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk , 2018, Familial Cancer.

[7]  O. Olopade,et al.  Mutations in context: implications of BRCA testing in diverse populations , 2017, Familial Cancer.

[8]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[9]  T. Naab,et al.  Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. , 2017, Ethnicity & disease.

[10]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[11]  S. Grover,et al.  An update on the management of breast cancer in Africa , 2017, Infectious Agents and Cancer.

[12]  E. Thompson,et al.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Nathanson,et al.  Population Frequency of Germline BRCA1/2 Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Addissie,et al.  A Review on Breast Cancer Care in Africa , 2015, Breast Care.

[15]  A. Monteiro,et al.  A high frequency of BRCA mutations in young black women with breast cancer residing in Florida , 2015, Cancer.

[16]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Narod,et al.  The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[18]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Walsh,et al.  Inherited predisposition to breast cancer among African American women , 2014, Breast Cancer Research and Treatment.

[20]  S. Cederbaum,et al.  BLOOD AMMONIA AND GLUTAMINE AS PREDICTORS OF HYPERAMMONEMIC CRISES IN UREA CYCLE DISORDER PATIENTS , 2014, Genetics in Medicine.

[21]  D. Huo,et al.  An Epidemiologic Investigation of Physical Activity and Breast Cancer Risk in Africa , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[22]  Alex Rodriguez,et al.  Experiences building Globus Genomics: a next‐generation sequencing analysis service using Galaxy, Globus, and Amazon Web Services , 2014, Concurr. Comput. Pract. Exp..

[23]  C. Adebamowo,et al.  Alcohol Consumption and Breast Cancer Risk among Women in Three Sub-Saharan African Countries , 2014, PloS one.

[24]  Ian T. Foster,et al.  Efficient and Secure Transfer, Synchronization, and Sharing of Big Data , 2014, IEEE Cloud Computing.

[25]  A. Godwin,et al.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing , 2014, Breast Cancer Research and Treatment.

[26]  L. Brinton,et al.  Breast cancer in Sub-Saharan Africa: opportunities for prevention , 2014, Breast Cancer Research and Treatment.

[27]  P. Marcom,et al.  Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort , 2013, Annals of Surgical Oncology.

[28]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[29]  A. Monteiro,et al.  Early Onset Breast Cancer in a Registry‐based Sample of African‐American Women: BRCA Mutation Prevalence, and Other Personal and System‐level Clinical Characteristics , 2013, The breast journal.

[30]  E. John,et al.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  O. Olopade,et al.  High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients , 2012, International journal of cancer.

[32]  M. C. Leske,et al.  Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry , 2012, Breast Cancer Research and Treatment.

[33]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[34]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[35]  A. Kurian.  BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications , 2010, Current opinion in obstetrics & gynecology.

[36]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[37]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[38]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[39]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[41]  Giske Ursin,et al.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.

[42]  R. Eeles,et al.  Radiotherapy and genetic predisposition to breast cancer. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[43]  L. Esserman,et al.  Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.

[44]  R. Stock,et al.  ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. , 2002, International journal of radiation oncology, biology, physics.

[45]  S. Seal,et al.  BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Katherine M. Tucker,et al.  The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in australian Ashkenazi Jews , 2001, Cancer.

[47]  S. Seal,et al.  Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Giles,et al.  Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). , 1999, Journal of the National Cancer Institute. Monographs.

[49]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[50]  M. King,et al.  Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. , 1998, JAMA.

[51]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[52]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[53]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.

[54]  S. Miller,et al.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2012 .

[55]  G. Casey,et al.  Frequency of BRCA1 and BRCA2 mutations in a clinic‐based series of breast and ovarian cancer families , 2001, Human mutation.